FDA supports tighter restrictions on hydrocodone
WASHINGTON — The Food and Drug Administration is recommending tighter restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the United States.
In a major policy shift, the agency said in an online notice on Thursday that hydrocodone-containing drugs should be subject to the same restrictions as other narcotic drugs such as oxycodone and morphine.
More than a decade has passed since the Drug Enforcement Agency asked the FDA to reclassify hydrocodone so that it would be subject to the same restrictions as other opioid drugs. The FDA did not issue a formal announcement about its decision, which has long been sought by many patient advocates, doctors and lawmakers.
In early December, the FDA says it will formally request that hydrocodone be classified as a Schedule II drug, limiting who can write a prescription and how many times it can be refilled.
Show commenting policy
TribLive commenting policy
- IBM’s Watson supercomputing system to be applied to PTSD
- Pair of NYC officers killed in ambush shooting
- 3-D printed prosthetics give dog ability to run
- Poor morale, training in Air Force ICBM program spur questions about usefulness as nuclear deterrent
- Document hunt to begin for illegals who need proof of residency since 2010 for permit, reprieve
- Financial fraudster used investors’ lucre to freeze dead wife, feds contend
- Killer of New York police officers angry over Garner chokehold death, officials say
- Teenager who attacked California Highway Patrol officer with machete shot, killed
- 4 Afghans freed from Guantanamo
- N.Y. reports crime decrease, credits ‘broken windows’
- Cat saved from California storm drain after 2 weeks